We were delighted to be able to speak with Lluís Puig (Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain) about novel pathophysiology-based therapeutic agents in the treatment of psoriasis. His full presentation entitled ‘New therapeutic targets based on pathophysiology’ was presented at the EADV Virtual Congress 2020.
- Could you give us a brief overview of the most well known cytokines in the pathogenesis of psoriasis? (0:13)
- What have we learned about the role of IL-36 in the pathogenesis of plaque psoriasis? (1:20)
- What therapeutic agents targeting IL-36 have been developed? (3:02)
- What other molecules in the IL-1 superfamily may be useful therapeutic targets? (4:22)
Disclosures: Lluís Puig has received consultancy/speaker’s honoraria from and/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, JS BIOCAD, Leo-Pharma, Lilly, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EADV 2020 Virtual Congress.
Share this Video
Related Videos In Psoriasis
Leon Kircik, AAD VMX 2021: Roflumilast Foam in Scalp and Body Psoriasis
Prof. Leon Kircik (Icahn School of Medicine at Mount Sinai, New York, NY, USA) kindly took the time to speak with us about the results from the recent phase 2b study investigating roflumilast foam in the treatment of scalp and body psoriasis. His abstract entitled ‘Once-daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A […]
Kim Papp, AAD VMX 2021: Secukinumab PURE Study
We were delighted to discuss with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) results from the PURE study (NCT02786186), designed to investigate the long-term safety profile of secukinumab in patients with moderate to severe chronic plaque psoriasis. The abstract ‘Secukinumab helps achieving clear/almost clear skin and improve quality of life in psoriasis over […]
Siew Eng Choon, AAD VMX 2021: Unmet Needs in Generalised Pustular Psoriasis
It was a pleasure to speak with Dr Siew Eng Choon (Monash University, Malaysia) about the current unmet needs in the treatment of generalised pustular psoriasis (GPP). Disclosures: Dr Siew Eng Choon has received honoraria for serving as a consultant, advisory board member, and/or speaker for AbbVie, Boehringer Ingelheim, Janssen, Leo, Eli Lilly, Leo, Novartis, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!